What Are The Active Ingredients In Stugeron?

Stugeron Powder is a widely used medication known for its effectiveness in treating various conditions, particularly motion sickness and vertigo. The active ingredient in Stugeron is cinnarizine, a calcium channel blocker that works by affecting the inner ear and brain to reduce symptoms associated with balance disorders. Understanding the active ingredients in Stugeron is crucial for patients and healthcare providers to ensure proper usage and maximize its therapeutic benefits.

How does cinnarizine work in Stugeron?

Cinnarizine, the primary active ingredient in Stugeron, operates through multiple mechanisms to alleviate symptoms of motion sickness and vertigo. As a calcium channel blocker, it primarily works by inhibiting the influx of calcium ions into cells, particularly in the vestibular system and cerebral blood vessels. This action has several important effects on the body:

1. Vestibular system regulation: Cinnarizine helps to stabilize the vestibular system, which is responsible for maintaining balance and spatial orientation. By modulating calcium influx in the vestibular hair cells, it reduces their sensitivity to movement and changes in position. This action helps to decrease the conflicting signals sent to the brain during motion, which are often the root cause of motion sickness and vertigo.
2. Cerebral blood flow improvement: The medication also acts on the blood vessels in the brain, promoting better blood flow. This improved circulation can help reduce symptoms of vertigo and dizziness by ensuring adequate oxygen and nutrient supply to the brain tissues involved in balance and spatial awareness.
3. Antihistamine effects: Cinnarizine exhibits mild antihistamine properties, which can contribute to its effectiveness in treating motion sickness. Histamine is involved in the body's response to motion and can trigger symptoms like nausea and vomiting. By partially blocking histamine receptors, cinnarizine helps to mitigate these symptoms.
4. Neuroprotective properties: Some studies suggest that cinnarizine may have neuroprotective effects, potentially benefiting patients with certain neurological disorders. This aspect of its action is still being researched but could explain its broader applications in treating various balance and neurological conditions.

The multifaceted action of cinnarizine makes Stugeron Powder an effective treatment for a range of balance-related disorders. Its ability to address both the neurological and vascular aspects of these conditions contributes to its widespread use and efficacy. Patients typically experience a reduction in dizziness, nausea, and other symptoms associated with motion sickness and vertigo within a short time after taking the medication.

It's important to note that while cinnarizine is highly effective for many patients, its use should be guided by a healthcare professional. The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient's response to the medication.

What is the recommended dosage for Stugeron?

The recommended dosage for Stugeron varies depending on the condition being treated and the patient's age. It's crucial to follow the prescribing physician's instructions or the guidelines provided in the medication's package insert. However, general dosage recommendations are as follows:

• For motion sickness prevention:
  • Adults and children over 12 years: Usually 30 mg (one tablet) taken 2 hours before travel, followed by 15 mg (half a tablet) every 8 hours during the journey if needed.
  • Children 5-12 years: Half the adult dose is typically recommended.
• For vertigo and other balance disorders:
  • Adults: The usual dose is 30 mg three times daily, taken with or after meals.
  • Elderly patients: May start with a lower dose of 15 mg three times daily, which can be increased if necessary.

It's important to note that these are general guidelines, and the actual prescribed dose may differ based on individual factors such as the severity of symptoms, patient's age, weight, and overall health condition. Patients should always consult their healthcare provider for personalized dosage instructions.

The timing of Stugeron intake is also crucial for its effectiveness, especially when used for motion sickness prevention. Taking the medication about 2 hours before travel allows it to reach therapeutic levels in the bloodstream by the time the journey begins. For ongoing treatment of vertigo or balance disorders, consistent timing of doses throughout the day helps maintain steady levels of the medication in the body.

Patients should be aware that the full effect of Stugeron Powder may not be immediate, particularly when used for chronic conditions. It may take several days of regular use before the maximum benefit is achieved. Therefore, patience and adherence to the prescribed regimen are important for optimal results.

In cases where a dose is missed, patients should take it as soon as they remember, unless it's almost time for the next scheduled dose. In such cases, they should skip the missed dose and continue with their regular dosing schedule. It's crucial never to double up on doses to make up for a missed one, as this can increase the risk of side effects.

For long-term use, regular follow-ups with the prescribing physician are recommended to assess the medication's effectiveness and make any necessary adjustments to the dosage or treatment plan. This is particularly important for elderly patients or those with underlying health conditions, as they may be more sensitive to the effects of the medication.

Are there any interactions between Stugeron and other medications?

Understanding potential drug interactions is crucial when taking Stugeron (cinnarizine) to ensure safe and effective treatment. While Stugeron is generally well-tolerated, it can interact with various medications, potentially altering their effectiveness or increasing the risk of side effects. Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting Stugeron.

Some notable interactions include:

1. Central Nervous System (CNS) Depressants: Stugeron may enhance the sedative effects of CNS depressants such as alcohol, barbiturates, opioids, and benzodiazepines. This combination can lead to increased drowsiness and impaired cognitive function. Patients should avoid or limit alcohol consumption while taking Stugeron and use caution when taking other sedating medications.
2. Anticholinergic Medications: Drugs with anticholinergic properties, such as some antidepressants, antihistamines, and medications for overactive bladder, may have their effects amplified when combined with Stugeron. This can result in increased dry mouth, constipation, blurred vision, and urinary retention.
3. Antihypertensive Medications: Stugeron may potentiate the effects of blood pressure-lowering medications. Patients taking antihypertensives should have their blood pressure monitored regularly when starting or adjusting Stugeron dosage.
4. Monoamine Oxidase Inhibitors (MAOIs): The combination of Stugeron with MAOIs can potentially lead to a hypertensive crisis. It's generally recommended to avoid this combination or use it only under close medical supervision.
5. Anticonvulsants: Some anticonvulsant medications may have their effectiveness reduced when taken with Stugeron. Patients with epilepsy should be monitored closely for any changes in seizure control.
6. CYP2D6 Substrates: Cinnarizine is metabolized by the CYP2D6 enzyme system. Medications that are also metabolized by this system (such as certain antidepressants, antipsychotics, and beta-blockers) may interact with Stugeron Powder, potentially altering their effectiveness or increasing side effects.

It's important to note that this list is not exhaustive, and other interactions may occur. Healthcare providers should conduct a thorough medication review before prescribing Stugeron and monitor patients for any unexpected effects or changes in their condition.

Patients should also be aware that certain medical conditions may affect the use of Stugeron. For instance, those with Parkinson's disease, liver or kidney problems, or a history of depression should use Stugeron with caution and under close medical supervision.

In conclusion, while Stugeron is an effective medication for treating motion sickness and vertigo, its use requires careful consideration of potential drug interactions and individual patient factors. Open communication between patients and healthcare providers is essential to ensure safe and effective treatment with Stugeron Powder.

If you are also interested in this product and want to know more product details, or want to know about other related products, please feel free to contact sasha_slsbio@aliyun.com.

References:

1. British National Formulary (BNF). "Cinnarizine." Accessed [Date].
2. Drugbank. "Cinnarizine." 
3. European Medicines Agency. "Cinnarizine." 
4. Golding, J. F., & Gresty, M. A. (2015). Motion sickness. Current opinion in neurology, 28(1), 83-88.
5. Godfraind, T. (2014). Calcium channel blockers in cardiovascular pharmacotherapy. Journal of cardiovascular pharmacology and therapeutics, 19(6), 501-515.
6. Hain, T. C., & Uddin, M. (2003). Pharmacological treatment of vertigo. CNS drugs, 17(2), 85-100.
7. Martínez‐Vila, E., Fragoso, M., Sánchez‐Menoyo, J. L., & Martínez‐Ramírez, S. (2001). Cinnarizine in the prophylaxis of migraine: a review. Revista de neurologia, 33(11), 1060-1069.
8. Medicines.org.uk. "Stugeron 15 - Summary of Product Characteristics (SmPC)." 
9. Pianese, C. P., Hidalgo, L. O., González, R. H., Madrid, C. E., Ponce, J. E., Ramírez, A. M., ... & Villanueva, L. G. (2002). New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study. Otology & Neurotology, 23(3), 357-363.
10. Scholtz, A. W., Steindl, R., Burchardi, N., Bognar-Steinberg, I., & Baumann, W. (2012). Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study. Clinical drug investigation, 32(6), 387-399.